• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[乳腺癌分子分类与预后关系的研究]

[A study on the relationship between breast cancer molecular classification and prognosis].

作者信息

Chen Xiao-Song, Ma Chuan-Dong, Chen Can-Ming

机构信息

Department of Oncology, Shanghai Medical College, Shanghai 200032, China.

出版信息

Zhonghua Wai Ke Za Zhi. 2008 Sep 15;46(18):1400-3.

PMID:19094512
Abstract

OBJECTIVE

To investigate the relationship between breast cancer molecular classification and prognosis.

METHODS

From January 2002 to December 2003, 708 female primary breast cancer patients with a mean age of 53 years old were retrospectively analyzed. The classification of breast cancer was according to the immunohistochemical results of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor (HER2) status. Molecular classification definitions included highly endocrine responsive, incompletely endocrine responsive, triple negative, and HER2 positive. The prognosis among different molecular classifications of breast cancer was investigated. The survival rates of different classifications were compared by Log-rank test.

RESULTS

The proportion of highly endocrine responsive, incompletely endocrine responsive, HER2 positive and triple-negative breast cancer was 33.2% (235/708), 23.6% (167/708), 21.3% (151/708) and 21.9% (155/708). The follow-up period were from 3 to 68 months with a median of 40.2 months. A total of 100 cases were identified to had disease recurrence or death. Factors affecting the prognosis were tumor size, axillary lymph node status, molecular classification, adjuvant radiotherapy and adjuvant endocrine therapy by univariate analysis. Multivariate analysis revealed that the molecular classification and lymph node status were the independent prognostic factors with the hazard ratio 1.205 (P = 0.047) and 4.512 (P = 0.000), respectively. Survival analysis showed that highly endocrine responsive breast cancer was with superior prognosis versus others.

CONCLUSIONS

Molecular classification of breast cancer is an independent predictor of prognosis. Breast cancer patients classified as highly endocrine responsive subtype have the best outcome.

摘要

目的

探讨乳腺癌分子分类与预后的关系。

方法

回顾性分析2002年1月至2003年12月期间708例平均年龄53岁的女性原发性乳腺癌患者。乳腺癌的分类依据雌激素受体(ER)、孕激素受体(PR)和人表皮生长因子受体(HER2)状态的免疫组化结果。分子分类定义包括高度内分泌反应型、不完全内分泌反应型、三阴性和HER2阳性。研究乳腺癌不同分子分类的预后情况。采用对数秩检验比较不同分类的生存率。

结果

高度内分泌反应型、不完全内分泌反应型、HER2阳性和三阴性乳腺癌的比例分别为33.2%(235/708)、23.6%(167/708)、21.3%(151/708)和21.9%(155/708)。随访时间为3至68个月,中位时间为40.2个月。共确定100例出现疾病复发或死亡。单因素分析显示,影响预后的因素有肿瘤大小、腋窝淋巴结状态、分子分类、辅助放疗和辅助内分泌治疗。多因素分析显示,分子分类和淋巴结状态是独立的预后因素,风险比分别为1.205(P = 0.047)和4.512(P = 0.000)。生存分析表明,高度内分泌反应型乳腺癌的预后优于其他类型。

结论

乳腺癌的分子分类是预后的独立预测因素。分类为高度内分泌反应型亚型的乳腺癌患者预后最佳。

相似文献

1
[A study on the relationship between breast cancer molecular classification and prognosis].[乳腺癌分子分类与预后关系的研究]
Zhonghua Wai Ke Za Zhi. 2008 Sep 15;46(18):1400-3.
2
[Clinicopathological characteristics and prognostic factors of breast cancer with estrogen- and progesterone-receptor negative and HER-2 overexpression].雌激素和孕激素受体阴性且HER-2过表达乳腺癌的临床病理特征及预后因素
Zhonghua Zhong Liu Za Zhi. 2008 Dec;30(12):917-20.
3
LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.LEA-135表达:其与淋巴结阳性原发性浸润性乳腺癌患者较低的复发风险及总生存期延长的相关性。
Anticancer Res. 2004 Jul-Aug;24(4):2391-400.
4
Is triple negative a prognostic factor in breast cancer?三阴性是乳腺癌的一个预后因素吗?
Breast Cancer. 2008;15(4):303-8. doi: 10.1007/s12282-008-0042-3. Epub 2008 Mar 29.
5
[Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].[不同分子亚型可手术乳腺癌患者的临床特征与生存情况]
Zhonghua Zhong Liu Za Zhi. 2009 Jun;31(6):447-51.
6
[Clinical characteristics and prognosis of breast cancer patients with vascular invasion].[伴有血管侵犯的乳腺癌患者的临床特征及预后]
Zhonghua Zhong Liu Za Zhi. 2007 Feb;29(2):137-40.
7
[Clinical characteristics and prognosis of different subtypes of breast cancer].[乳腺癌不同亚型的临床特征与预后]
Zhonghua Zhong Liu Za Zhi. 2008 Jun;30(6):456-61.
8
[Clinical features and prognosis analysis of different breast cancer molecular subtypes].不同乳腺癌分子亚型的临床特征及预后分析
Zhonghua Zhong Liu Za Zhi. 2011 Jan;33(1):42-6.
9
Characterization of breast cancer subtypes by quantitative assessment of biological parameters: relationship with clinicopathological characteristics, biological features and prognosis.通过生物参数的定量评估对乳腺癌亚型进行特征分析:与临床病理特征、生物学特性及预后的关系
Eur J Obstet Gynecol Reprod Biol. 2008 Dec;141(2):147-52. doi: 10.1016/j.ejogrb.2008.07.021. Epub 2008 Sep 2.
10
HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information.激素受体阳性的绝经前原发性乳腺癌中的HER2状态可提供预后信息,但不能预测他莫昔芬的治疗效果。
Breast Cancer Res Treat. 2008 May;109(2):351-7. doi: 10.1007/s10549-007-9660-2. Epub 2007 Jul 18.

引用本文的文献

1
Altered Leukocyte Sphingolipid Pathway in Breast Cancer.乳腺癌中白细胞鞘脂代谢途径的改变。
Int J Mol Sci. 2017 Nov 24;18(12):2521. doi: 10.3390/ijms18122521.